Merck & Co.’s Keytruda Gets Fighting Chance In TNBC
Successful KEYNOTE-522 Results May Sway FDA
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.
You may also be interested in...
Merck unveiled event-free survival results for Keytruda in triple-negative breast cancer following failure earlier this year to gain approval on a surrogate endpoint.
Merck & Co. unveiled event-free survival data for Keytruda in triple-negative breast cancer, following a failure earlier this year to gain approval on a surrogate endpoint.
The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.